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Summary 
Triglyceride-rich lipoproteins bind and inactivate bacterial endotoxin in vitro and prevent death 
when given before a lethal dose of endotoxin in animals. However, lipoproteins have not yet 
been demonstrated to improve survival in polymicrobial gram-negative sepsis. We therefore tested 
the ability of triglyceride-rich lipoproteins to prevent death after cecal ligation and puncture 
(CLP) in rats.  Animals were given bolus infusions of either chylomicrons (1 g triglyceride/kg 
per 4 h) or an equal volume of saline for 28 h  after CLP.  Chylomicron infusions significantly 
improved survival (measured at 96 h) compared with saline  controls (80 vs 27%,  P  ~<0.03). 
Chylomicron infusions also reduced serum levels of endotoxin, measured 90 min (26  _+  3 vs 
136  __  51 pg/ml, mean  +  SEM, P ~<0.03) and 6 h (121 +_  54 vs 1,026  _+ 459 pg/ml, P ~<0.05) 
after CLP. The reduction in serum endotoxin correlated with a reduction in serum tumor necrosis 
factor, measured 6 h after CLP (0 +- 0 vs 58  __. 24 pg/ml, P ~<0.03), suggesting that chylomicrons 
improve survival in this modal by limiting macrophage exposure to endotoxin and thereby reducing 
secretion of inflammatory cytokines. Infusions of a synthetic triglyceride-rich lipid emulsion (In- 
tralipid; KabiVitrum, Inc., Alameda, CA) (1 g triglyceride/kg) also significantly improved sur- 
vival compared with saline controls (71 vs 27%, P ~<0.03). These data demonstrate that triglyceride- 
rich lipoproteins can protect animals from lethal polymicrobial gram-negative sepsis. 
O 
ne of the earliest and most consistent metabolic responses 
to endotoxin is an increase in plasma levels of triglycer- 
ide, due to an increase in triglyceride-rich very low density 
lipoprotein (VLDL) (1). This endotoxin-stimulated increase 
in circulating triglyceride-rich particles may have a protec- 
tive function,  as triglyceride-rich lipoproteins  (VLDL and 
chylomicrons) have been shown to bind and inactivate endo- 
toxin (2,  3).  Previous work in our laboratory has demon- 
strated that both chylomicrons and VLDL can inhibit the 
detection of significant quantities of endotoxin (>/1 ng of 
endotoxin/mg of particle triglyceride) by the limulus assay 
in vitro (4). Triglyceride-rich lipoproteins also reduce endo- 
toxin toxicity in vivo.  Chylomicrons and VLDL have been 
shown to protect animals from death when incubated with 
a  lethal  dose  of endotoxin  before  administration  (2,  3). 
This work was presented  in abstract form  at the Clinical Research  Meeting 
of the American  Federation  of Clinical Research  in Washington, DC, 29 
April-3 May 1993. 
Chylomicrons also prevent death in animals when given as 
a separate intravenous infusion just before endotoxin adminis- 
tration (3). 
In addition to inhibiting endotoxin activity directly, triglyc- 
eride-rich lipoproteins also alter endotoxin metabolism, which 
may contribute to their protective effect in these animal models. 
When administered with chylomicrons, the clearance of endo- 
toxin from plasma is accelerated (3), with increased endo- 
toxin uptake by the liver (3), shunting of endotoxin to hepa- 
tocytes and away from hepatic macrophages (Kupffer cells) 
(3),  and increased endotoxin excretion in bile (5).  There is 
a concomitant decrease in serum TNF levels (3), suggesting 
that chylomicrons shield the organism from endotoxin-induced 
macrophage activation and cytokine secretion by accelerating 
endotoxin delivery to hepatocytes. 
The purpose of the present study was to determine whether 
triglyceride-rich lipoproteins would lessen the toxicity of en- 
dotoxin generated endogenously during polymicrobial sepsis. 
We performed cecal ligation and puncture (CLP) in rats,  a 
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polymicrobial bacteremia (predominantly gram negative), en- 
dotoxemia,  and a 60--80%  mortality by 72 h  (6, 7). Inter- 
mittent intravenous infusions of chylomicrons significantly 
improved survival after CLP while reducing serum levels of 
endotoxin and TNF. Infusions of a synthetic triglyceride-rich 
lipid emulsion also significantly improved survival after CLP. 
Materials and Methods 
Reagents and Solutions.  Glacial acetic acid (Fisher Chemical Co., 
Fairlawn, NJ); NaOH (J. T. Baker, Inc., Pittsburgh, PA); apyro- 
genic, preservative-free 0.9%  NaC1 (Kendall  McGraw Laborato- 
ries, Inc., Irvine, CA), and H20 (Elkins-Sinn, Inc., Cherry Hill, 
NJ); 3% H202 (Cumberland Co., Smyrna, TN); heparin sodium 
salt (Sigma Chemical Co., St. Louis, MO); and Intralipid 20% in- 
travenous lipid emulsion containing 20% soybean oil (triglyceride), 
1.2% egg yolk phospholipid, and 2.25%  glycerin were used as 
specified. The PBS used in all experiments was tested by a chromo- 
genic modification of the limulus assay (8) as we have used previ- 
ously (2) and was found to be free of detectable endotoxin (<10 
pg endotoxin/ml). 
Det~rogenation.  To avoid contamination with exogenously de- 
rived endotoxin, all heat-stable materials used in the isolation, pro- 
cessing, and assay of solutions to be injected into the rats, including 
test tubes, flasks, stoppers, beakers, and pipettes, were rendered sterile 
and free of detectable endotoxin (<5-10 pg/ml) by steam autoclaving 
followed by dry heating at 180~  for a minimum of 4 h, as previ- 
ously reported (2). 
Ckylomicron Collection.  Mesenteric lymph containing nascent 
chylomicrons was obtained by cannulation of the mesenteric lymph 
duct of male Sprague-Dawley rats (250-350 g, Bantin and Kingman, 
Inc., Fremont, CA) gavage fed a mixture of corn oil and milk, 
as previously described (3). Special precautions were taken to avoid 
the introduction of exogenous endotoxin during the collection pro- 
cess, as previously described (2).  The triglyceride content of the 
mesenteric lymph was determined using a standard enzymatic assay 
(Sigma Chemical Co.) and varied between 75 and 100 mg triglyc- 
eride/ml. 
Chflomicron TriglFeride Clearance.  Male Sprague-Dawley rats 
(250-280 g) were anesthetized with pentobarbital (50 mg/kg i.p.) 
and catheterized via the ileofemoral vein. Animals received an in- 
travenous bolus infusion of mesenteric lymph containing nascent 
chylomicrons (1 g triglyceride/kg) or Intralipid (1 g triglyceride/ 
kg). 400-/A blood samples were drawn before and 5, 15, 60,  120, 
180, and 240 rain after infusion. After centrifugation (2,000 rpm 
for 10 min),  the triglyceride content of plasma  was  determined 
using standard enzymatic assays. All animal procedures were per- 
formed in accordance with the guidelines of the Animal Studies 
Subcommittee (Department of Veterans  Affairs Medical Center, 
San Francisco). 
Sepsis Model  (CLP).  Male Sprague-Dawley rats (240-280 g) un- 
derwent placement of an internal jugular vein catheter (MRE-040 
polyethylene tubing), which was tunneled to the back and con- 
nected to a subcutaneous port 0elco intermittent injection cap; 
Critikon, Inc., Irvine, CA) while under pentobarbital anesthesia. 
The cannula and port were then flushed with 0.3 ml apyrogenic 
heparin (50 U/ml). The animals were allowed to fully recover over- 
night with free access to food and water. 
24 h after insertion of the venous cannulae, the animals under- 
went CLP, as previously described (6, 7). Under light ether anes- 
thesia, a 1-cm midline abdominal incision was made and the cecum 
was delivered into the wound. The avascular portion of the mesen- 
tery was sharply incised.  The distal cecum was ligated with 4-0 
silk suture (so as not to interrupt the flow of intestinal contents), 
and two punctures were made on the antimesenteric border of the 
distal cecum with an 18-gauge needle.  The cecum was returned 
to the abdomen, and the abdominal wall was dosed in layers. The 
rats were returned to their cages and allowed free access to food 
and water. Beginning at the time of CLP, animals received intrave- 
nous bolus infusions of either mesenteric lymph containing nascent 
chylomicrons (1 g triglyceride/kg, 75 mg triglyceride/ml),  Intralipid 
(1 g  triglyceride/kg, 200 mg triglyceride/ml), or normal saline 
(volume equivalent to that of the chylomicron dose).  Bolus infu- 
sions were administered every 4 h for 28 h and were followed by 
heparin flush. The 4-h dosing interval allowed plasma triglyceride 
levels to return  to baseline just  before the  subsequent  dose of 
chylomicrons or  Intralipid  (Fig.  1).  Animals  were fed ad  lib. 
throughout. The animals were observed continuously during the 
first 28 h after CLP. Mortality was also determined at 48, 72, and 
96 h  after CLP. 
Serum Endotoxin and TNE  To determine endotoxin and TNF 
levels after CLP, the study was repeated as described above, with 
infusion of mesenteric lymph containing nascent chylomicrons or 
normal saline (controls). At various time intervals after CLP, the 
animals were killed and blood samples were taken from the aorta. 
After collection of serum, samples were assayed for endotoxin by 
a chromogenic modification of the limulus assay (8). Serum samples 
were diluted 1/10 with apyrogenic saline and heated at 75~  for 
5 rain before the limulus assay to remove the effect of serum in- 
hibitors of the assay (8)  and specifically to liberate lipoprotein- 
bound endotoxin (9). Serum TNF levels were measured via a cyto- 
toxicity assay using WEHI 164 clone 13 cells with development 
using thiazolyl blue (10). 
StatisticalAnalysis.  Statistical significance for the mortality data 
was determined by chi square analysis, measured 96 h after CLP. 
Serum endotoxin and TNF levels were compared using Kruskal- 
Wallis  analysis. 
Results 
Ckylomicron Triglyceride Clearance (Fig. 1).  Infusion of 1 g 
triglyceride/kg of chylomicrons or Intralipid produced an early 
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Figure  1.  Chylomicron/Intralipid triglyeeride  clearance. Rats received 
an intravenous infusion of chylomicrons (1 g triglyceride/kg) or the syn- 
thetic triglyceride-rich  lipid emulsion Intralipid (1 g triglyceride/kg).  Serial 
blood samples were obtained and plasma was assayed  for triglyceride.  Data 
are mean _+ SEM of four animals per group. Values were estimated from 
an enzymatic assay for glycerol. Therefore, these values may be 20% or 
more higher than actual circulating plasma values during chylomicron  or 
Intralipid infusions. 
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cleared from the circulation. The maximal elevation of plasma 
tfiglyceride, as measured 5 min after infusion, was greater 
with infusion of chylomicrons than with Intralipid, but the 
clearance patterns were otherwise similar. Plasma triglyceride 
levels returned to baseline 4 h after infusion. Plasma triglyceride 
levels were measured by determining glycerol levels. Because 
the infusions of triglyceride with chylomicrons or Intralipid 
can raise plasma glycerol levels, the plasma triglyceride levels 
may be overestimated by 20%  or more. 
Survival after CLP (Fig. 2).  Survival, measured 96 h after 
CLP, was significantly improved in those animals receiving 
chylomicrons (80%) and Intralipid (71%) compared with con- 
trols (27%) (P ~0.03 vs controls for both chylomicron- and 
Intralipid-treated groups). All deaths occurred within the first 
72 h, with the majority of deaths in all groups occurring 
between 24 and 48 h after CLP. All animals appeared ill ini- 
tially, with ruffled fur, huddling behavior, and diarrhea. By 
96 h after CLP, survivors had returned to normal behavior 
patterns,  while piloerection and diarrhea had ceased. 
Serum Endotoxin after CLP (Fig. 3).  Serum endotoxin levels 
were significantly less in chylomicron-treated animals than 
in controls at both 90 min and 6 h after CLP. Serum samples 
were diluted and heated before the limulus assay to remove 
the effect of serum inhibitors of the assay (8) and to liberate 
lipoprotein-bound endotoxin (9). Thus, the observed reduc- 
tion in endotoxin activity represents a decrease in total cir- 
culating endotoxin rather than inhibition of the activity of 
lipoprotein-bound endotoxin. 
Serum TNF after CLP (Fig. 4).  Serum TNF was also signi- 
ficantly reduced by chylomicron treatment at 6 h after CLP 
(undetectable in chylomicron-treated animals.)  At 90 min 
after CLP there was also a trend towards a reduction in TNF 
levels, but the difference did not reach statistical significance 
(P  =  0.19). 
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Figure  3.  Serum endotoxin (LPS) levels after CLE Rats underwent in- 
terual juguhr vein catheter placement and CLP as described above. Intra- 
venous infusions of mesenteric lymph containing nascent chylomierons 
(1 g triglyeeride/kg) or an equivalent volume of normal saline (controls) 
were administered at the time of CLP and every 4 h thereafter. Animals 
were killed either 90 min (n  =  16 in each group) or 6 h  (n  =  6 in each 
group) after CLP for serum collection. Serum endotoxin levels were deter- 
mined by a chromogenic modification of the limulus lysate assay (8). Data 
represent mean  +_ SEM for each group.  * P <0.05 versus saline controls. 
Discussion 
These data demonstrate that repeated doses of triglyceride- 
rich lipoproteins prolong survival while reducing serum en- 
dotoxin and TNF levels during lethal gram-negative sepsis. 
We chose to use CLP as a septic model because it creates 
a polymicrobial infection (7) similar to that seen in humans 
with intraabdominal sepsis. In addition, serum levels of en- 
dotoxin and inflammatory cytokines are lower and are sus- 
tained longer after CLP (7)  than after single injections of 
bacteria or endotoxin. The prolonged release of inflamma- 
tory mediators during CLP more closely resembles the pat- 
tern seen in septic patients  (11). 
Lethality of the CLP model may vary as a function of the 
volume of stool in the cecum at the time of ligation and 
the amount of stool mechanically expressed before returning 
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Figure  2.  Survival of rats after CLE Animals underwent placement of 
indwelling venous catheters, and 24 h later they underwent CLP. Begin- 
ning at the time of CLP, animals received intravenous infusions of either 
mesenteric lymph containing nascent chylomicrons (1 g  triglyceride/kg, 
n  =  15), Intralipid (1 g triglyceride/kg, n  =  17), or normal saline (volume 
equivalent to that of the chylomicron dose, n  =  15). Infusions were ad- 
ministered every 4 h  for 28 h. Survival was determined up to 96 h. All 
deaths occurred during the first 72 h  after CLP.  * P  ~0.03  vs controls 
at 96 h. 
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Figure 4.  Serum TNF levels after CLP. Rats underwent interualjugular 
vein catheter placement and CLP as described above. Intravenous infu- 
sions  of  mesenteric  lymph  containing  nascent  chylomicrons  (1  g 
triglyceride/kg) or an equivalent volume of normal saline (controls) were 
administered at the time of CLP and every 4 h  thereafter. Animals were 
killed either 90 min (n =  16 in each group) or 6 h (n =  6 in each group) 
after CLP for serum collection.  Serum TNF levels were determined by 
a cytotoxicity assay (10).  No TNF was detected in the serum of rats in 
the chylomicron-treated group killed 6 h after CLP. Data represent mean 
_+  SEM for each group.  * P  <0.05 vs saline controls. 
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investigator (T. E. Read) performed all CLP procedures.  A 
second investigator assigned animals to the various treatment 
groups. 
Previous work has demonstrated that triglyceride-rich li- 
poproteins protect animals from endotoxemic death via two 
complementary mechanisms: (a) by binding endotoxin and 
inhibiting its activity directly; and (b) by accelerating endo- 
toxin  clearance  from  plasma.  All  lipoproteins,  including 
triglyceride-rich VLDL (2) and chylomicrons (4), and cho- 
lesterol ester-rich HDL (2, 12-15) and LDL (2, 14, 15), have 
been shown to bind and inactivate endotoxin in vitro (as mea- 
sured by the limulus assay) and prevent endotoxin-induced 
death in animals. Ultrastructural studies of LDL-endotoxin 
complexes suggest that inhibition of endotoxin activity occurs 
via the insertion of the toxic lipid A moiety of endotoxin 
into the phospholipid surface of the lipoprotein particle (16). 
In addition to inhibiting detection of endotoxin by the limulus 
assay, lipoproteins also block the ability of endotoxin to in- 
duce secretion of the cytokines TNF, IL-1, and IL-6 from mac- 
rophages in cell culture (17, 18). During CLP, endotoxin 
bound to circulating triglyceride-rich particles would be effec- 
tively  hidden  from  the  reticuloendothelial  system,  thus 
reducing endotoxin-induced stimulation of macrophages. The 
secretion of inflammatory cytokines would therefore be lim- 
ited,  as is reflected  by the reduced TNF levels seen with 
chylomicron treatment after  CLP. 
Triglyceride-rich  lipoproteins may further shield the or- 
ganism from macrophage activation by redirecting endotoxin 
metabolism. Previous work in our laboratory has demonstrated 
that the clearance of chylomicron-bound  endotoxin is directed 
by the chylomicron rather than by the endotoxin molecule. 
When administered with chylomicrons, the clearance of en- 
dotoxin from plasma is accelerated, and uptake of endotoxin 
by the liver is increased (3). Autoradiographic data indicate 
that chylomicron-binding alters the cellular distribution of 
endotoxin uptake within the liver (3). Hepatic macrophages 
(Kupffer cells) clear the majority of an intravenous load of 
unbound endotoxin (19-22).  However, chylomicron/endo- 
toxin complexes,  like chylomicrons alone (23),  are rapidly 
cleared by hepatocytes (3). We have previously shown that 
the reduction in endotoxin uptake by Kupffer cells correlates 
with lower peak serum TNF levels (3). 
The lower serum endotoxin levels after CLP suggest that 
chylomicrons also accelerate endotoxin clearance during poly- 
microbial gram-negative sepsis. Before performing the limulus 
assay, serum samples were heated to liberate lipoprotein-bound 
endotoxin.  The reduction in endotoxin activity therefore 
represents a decrease in total circulating endotoxin, rather 
than inhibition of the activity of endotoxin bound to chylo- 
microns. The acceleration of endotoxin clearance from plasma 
may contribute to the reduction in serum TNF levels seen 
with chylomicron treatment after CLP. Thus, chylomicrons 
may improve survival during gram-negative sepsis  by inhibiting 
endotoxin activity and enhancing endotoxin clearance, both 
of which would limit macrophage exposure to endotoxin and 
thereby blunt an otherwise fatal cytokine response to en- 
dotoxemia. 
Intralipid particles exhibit many of the same properties as 
chylomicrons and may prevent septic death by a similar mech- 
anism. Chylomicron and Intralipid particles are both rich in 
triglyceride and are of similar size. Intralipid particles acquire 
apolipoproteins once in circulation (24) and, like chylomicrons 
(23), are rapidly cleared by hepatocytes (25). Synthetic triglyc- 
eride-rich emulsions, as well as chylomicrons, have the capa- 
city to inactivate endotoxin in vitro (4) and to prevent death 
from a lethal dose of endotoxin in animals  (2). 
Protection from endotoxemia and gram-negative sepsis by 
the administration of triglyceride-rich lipoproteins could be 
viewed as an augmentation of a natural host defense against 
infection. There is now growing evidence that triglyceride- 
rich lipoproteins are a component of the acute-phase response. 
When an organism is challenged with infectious agents, the 
liver increases production of an array of proteins, termed "acute- 
phase proteins" which are thought to enhance the natural 
defense against  infection and inflammation by a variety of 
mechanisms (26). The increase in hepatic synthesis and secre- 
tion of many of these proteins has been demonstrated to be 
mediated by inflammatory cytokines, including TNF (27, 28), 
IL-1 (28), and IL-6 (29, 30). Similarly, various inflammatory 
mediators, including endotoxin (1), interferons (31, 32), TNF 
(31, 33, 34),  IL-1 (32, 35),  and I1:6 (36), have been shown 
to increase hepatic fatty acid and VLDL synthesis or to de- 
crease lipoprotein lipase and lipid storage by adipocytes. These 
processes would increase (or maintain) plasma concentrations 
of triglyceride-rich lipoproteins during infection, which may 
represent an attempt by the body to neutralize the toxic effects 
of circulating endotoxin. 
The data presented here add to the growing evidence that 
lipoproteins can act as adjuncts to the immune system by 
decreasing the toxicity of a variety of harmful biological and 
chemical agents. Lipoproteins and apoproteins reduce the in- 
fectivity of several viruses (37-39) and parasites (40) and de- 
crease the inflammatory response to monosodium urate crystals 
(41). Thus, lipoproteins have significant antiinflammatory and 
antiinfectious properties aside from their role in lipid trans- 
port. Moreover, this study suggests that there may be a role 
for lipoproteins or lipid particles in the treatment of endotox- 
emia or gram-negative sepsis in humans. 
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